Institution
Pierre-and-Marie-Curie University
Education•Paris, France•
About: Pierre-and-Marie-Curie University is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Raman spectroscopy. The organization has 34448 authors who have published 56139 publications receiving 2392398 citations.
Topics: Population, Raman spectroscopy, Catalysis, Context (language use), Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, a generalized pre-averaging approach for estimating the integrated volatility is presented, which can generate rate optimal estimators with convergence rate n 1/4. But the convergence rate is not guaranteed.
525 citations
••
TL;DR: The use of 15N natural isotope tracing in an aquifer contained within chalk rocks in northern France indicates that, under certain hydrogeological conditions, major denitrification occurs.
524 citations
••
TL;DR: It is suggested that a particular antigen-binding site can be critical in determining the clinical features and outcome for at least some CLL patients.
524 citations
••
University of New South Wales1, Stony Brook University2, University of Barcelona3, University of Bonn4, Pierre-and-Marie-Curie University5, University of Paris6, Vita-Salute San Raffaele University7, Autonomous University of Barcelona8, Georgetown University9, University of North Carolina at Chapel Hill10, Federal University of Rio de Janeiro11, Rockefeller University12, University of Toronto13, Emory University14, Merck & Co.15
TL;DR: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score.
Abstract: Background We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed. Methods We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors. Genotyping of the integrase gene was performed in raltegravir recipients who had virologic failure. Results Virologic responses to raltegravir were consistently superior to responses to placebo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in optimized background therapy; or demographic characteristics. Among patients in the two studies combined who were using both enfuvirtide and darunavir for the first time, HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 89% of raltegravir recipients and 68% of placebo recipients. HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 69% and 80% of the raltegravir recipients and in 47% and 57% of the placebo recipients using either darunavir or enfuvirtide for the first time, respectively. At 48 weeks, 105 of the 462 raltegravir recipients (23%) had virologic failure. Genotyping was performed in 94 raltegravir recipients with virologic failure. Integrase mutations known to be associated with phenotypic resistance to raltegravir arose during treatment in 64 patients (68%). Forty-eight of these 64 patients (75%) had two or more resistance-associated mutations. Conclusions When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.)
524 citations
••
TL;DR: This cycle of neogenesis and redifferentiation caused by ectopic expression of Pax4 in alpha cells is capable of restoring a functional beta cell mass and curing diabetes in animals that have been chemically depleted of beta cells.
523 citations
Authors
Showing all 34671 results
Name | H-index | Papers | Citations |
---|---|---|---|
Zhong Lin Wang | 245 | 2529 | 259003 |
Guido Kroemer | 236 | 1404 | 246571 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
J. E. Brau | 162 | 1949 | 157675 |
E. Hivon | 147 | 403 | 118440 |
Kazuhiko Hara | 141 | 1956 | 107697 |
Simon Prunet | 141 | 434 | 96314 |
H. J. McCracken | 140 | 579 | 71091 |
G. Calderini | 139 | 1734 | 102408 |
Stefano Giagu | 139 | 1651 | 101569 |
Jean-Paul Kneib | 138 | 805 | 89287 |
G. Marchiori | 137 | 1590 | 94277 |
J. Ocariz | 136 | 1562 | 95905 |
Jean-Marie Tarascon | 136 | 853 | 137673 |
Alexis Brice | 135 | 870 | 83466 |